EPIMIRNA
"MicroRNAs in the Pathogenesis, Treatment and Prevention of Epilepsy"
| Coordinatore | ROYAL COLLEGE OF SURGEONS IN IRELAND
Organization address
address: Saint Stephen's Green 123 contact info |
| Nazionalità Coordinatore | Ireland [IE] |
| Sito del progetto | http://www.epimirna.eu/ |
| Totale costo | 15˙400˙505 € |
| EC contributo | 11˙586˙858 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-IP |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-09-01 - 2018-08-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ROYAL COLLEGE OF SURGEONS IN IRELAND
Organization address
address: Saint Stephen's Green 123 contact info |
IE (DUBLIN) | coordinator | 2˙418˙033.00 |
| 2 |
PHILIPPS UNIVERSITAET MARBURG
Organization address
address: Biegenstrasse 10 contact info |
DE (MARBURG) | participant | 2˙938˙045.00 |
| 3 |
SYDDANSK UNIVERSITET
Organization address
address: CAMPUSVEJ 55 contact info |
DK (ODENSE M) | participant | 620˙000.00 |
| 4 |
AARHUS UNIVERSITET
Organization address
address: Nordre Ringgade 1 contact info |
DK (AARHUS C) | participant | 519˙330.00 |
| 5 |
UNIVERSITATSKLINIKUM ERLANGEN
Organization address
address: Maximiliansplatz 2 contact info |
DE (ERLANGEN) | participant | 499˙328.00 |
| 6 |
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O
Organization address
address: Oskar-von-Miller-Ring 29 contact info |
DE (MUENCHEN) | participant | 490˙000.00 |
| 7 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 468˙983.00 |
| 8 |
BICOLL GMBH
Organization address
address: RICHARD RIEMERSCHMID ALLEE 27 contact info |
DE (MUENCHEN) | participant | 449˙880.00 |
| 9 |
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Organization address
address: AMSTERDAM AVENUE 1210 ROOM contact info |
US (NEW YORK) | participant | 433˙356.00 |
| 10 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 418˙085.00 |
| 11 |
INTERNA TECHNOLOGIES BV
Organization address
address: JONKERBOSPLEIN 52 contact info |
NL (NIJMEGEN) | participant | 405˙560.00 |
| 12 |
UNIVERSITA DEGLI STUDI DI VERONA
Organization address
address: VIA DELL ARTIGLIERE 8 contact info |
IT (VERONA) | participant | 399˙540.00 |
| 13 |
UNIVERSIDADE ESTADUAL DE CAMPINAS
Organization address
address: CIDADE UNIVERSITARIA ZEFERINO SN contact info |
BR (CAMPINAS SP) | participant | 380˙660.00 |
| 14 |
DIXI MICROTECHNIQUES SAS
Organization address
address: CHEMIN DE PALENTE 4 ESPACE contact info |
FR (BESANCON) | participant | 337˙502.00 |
| 15 |
BIOCOMPUTING PLATFORMS LTD OY
Organization address
address: TEKNIIKANTIE 14 contact info |
FI (ESPOO) | participant | 303˙900.00 |
| 16 |
DUKE UNIVERSITY
Organization address
address: BLACKWELL ST SUITE 920 324 contact info |
US (DURHAM) | participant | 271˙856.00 |
| 17 |
CERBOMED GMBH
Organization address
address: Henkestrasse 91 contact info |
DE (ERLANGEN) | participant | 232˙800.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Epilepsy is a major burden for patients and health systems worldwide. It is a common chronic neurological disorder affecting people of all ages, and the shortfall in existing treatments means that 30% of patients continue to suffer uncontrolled seizures. MicroRNAs (miRNA) are a recently-discovered, network-level layer of gene expression regulation that controls protein levels of entire signaling pathways. Research on miRNAs has unprecedented potential to (i) further our understanding of the underlying disease processes, (ii) deliver novel signatures and prognostic markers for response to therapy, and (iii) deliver novel therapeutics and drug targets. EpiMiRNA consortium members have pioneered discoveries on brain-specific miRNAs, established that miRNA changes are a feature of the pathophysiology of human temporal lobe epilepsy and have demonstrated experimentally that altering miRNA function can potently suppress epileptic seizures and seizure-damage. EpiMiRNA brings together experts on the neurobiology of miRNAs with the leading researchers working on miRNAs in epilepsy, epilepsy geneticists, leaders in miRNA-target detection, proteomics, and systems biology with research-intensive SMEs pursuing miRNA therapeutics and treatments for pharmacoresistant epilepsy. Through highly collaborative, inter-disciplinary and inter-sectorial research, EpiMiRNA will explain the mechanism by which miRNAs contribute to epileptogenesis, characterize genetic variation of miRNA in patients, evaluate seizure-suppressing effects of miRNAs in experimental models, identify novel miRNA modulatory molecules as potential future therapeutics, and develop miRNAs as prognostic markers to identify patients who respond to novel, non-pharmacological therapeutic interventions including brain stimulation. EpiMiRNA will generate the necessary critical mass in biomedical, clinical and industry/SME research to track, treat and prevent seizures and improve the clinical management of epilepsy patients.'
Introduzione (Teaser)
In Europe alone, around six million people suffer from epilepsy. EU-funded researchers are working on elucidating epilepsy pathogenesis and developing novel and effective RNA-based therapeutic strategies.
Descrizione progetto (Article)
Recent breakthroughs in science reveal that microRNAs (miRNAs) affect brain cell structure as well as function. miRNAs are non-coding RNA molecules critical for network-level regulation of gene expression. Epilepsy is a neurological disorder characterised by recurring seizures that may be associated with changes to brain levels of specific miRNAs that not only can serve as diagnostic/ prognostic markers, but that are also prime targets for novel approaches to treat epileptic seizures.
Under the aegis of the 'MicroRNAs in the pathogenesis, treatment and prevention of epilepsy' (http://www.epimirna.eu (EPIMIRNA)) project, scientists are working on identifying miRNA that are altered during epilepsy development and determining their contribution to epilepsy pathogenesis. For this purpose, they analyse miRNA levels in brain tissue and biofluids from different animal models as well as from epilepsy patients.
This project has set up already a high-throughput miRNA biofluid profiling platform that is highly sensitive and shows good reproducibility. Necessary protocols, cell lines and reporter assays for validating results with candidate miRNAs have been established.
While only at an early stage, specific microRNA profiles that may serve as diagnostic markers and/or become therapeutic targets have already been identified, f.ex. miRNA-134 was found to be upregulated in people with epilepsy.
Small, chemically modified double-stranded RNAs that mimic endogenous miRNAs to selectively upregulate miRNA expression, were made and tested.
A smart diagnostic 'combi' device has been developed and is clinically being tested in the project that allows for intracortical EEG and microdialysis sampling (to monitor miRNA levels) at the same time.
After obtaining the requisite ethical approvals, patient recruitment and sample collection is ongoing to investigate variants in miRNA sequence in the genome of epilepsy patients.
In parallel, researchers developed a computational model of a hippocampal pyramidal neuron along with single cell imaging methods. This will prove useful in quantifying neuronal excitability during miRNA-mediated changes.
Project activities will help identify miRNAs linked to epilepsy and improve our knowledge about this serious and disabling brain disease. This should prove useful in developing effective diagnostic and therapeutic strategies. Successful outcomes will improve the prognosis for millions of patients with epilepsy while boosting the competitiveness of the European biomedical industry.